By Benjamin Horney (December 12, 2020, 10:11 AM EST) -- AstraZeneca, advised by Freshfields, will buy Wachtell-guided Alexion for roughly $39 billion, the companies said Saturday, in a deal that represents the largest acquisition of a U.S. target this year and aims to bolster AstraZeneca's immunology capabilities.
The agreement calls for U.K.-based AstraZeneca PLC to pick up Massachusetts-headquartered Alexion Pharmaceuticals Inc.for a mixture of cash and stock, according to a statement.
Together, the companies say they'll be one of the world's leading pharmaceutical companies with the ability to develop treatments in a range of areas, including immunology, rare diseases, cancer and other illnesses. As part of the deal, AstraZeneca will establish...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!